Who are Indium-111 pentetreotide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/indium-111-pentetreotide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Indium-111 pentetreotide — Competitive Intelligence Brief

Indium-111 pentetreotide (Indium-111 pentetreotide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiolabeled somatostatin analog. Area: Oncology.

marketed Radiolabeled somatostatin analog Somatostatin receptors (SSTR2, SSTR5) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Indium-111 pentetreotide (Indium-111 pentetreotide) — Radio Isotope Therapy of America. Indium-111 pentetreotide is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells, allowing for diagnostic imaging and localization of these tumors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Indium-111 pentetreotide TARGET	Indium-111 pentetreotide	Radio Isotope Therapy of America	marketed	Radiolabeled somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiolabeled somatostatin analog class)

Radio Isotope Therapy of America · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Indium-111 pentetreotide — Competitive Intelligence Brief. https://druglandscape.com/ci/indium-111-pentetreotide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab